Condition
Diffuse Large B-cell-lymphoma
Total Trials
5
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 3 (2)
Trial Status
Unknown3
Recruiting1
Active Not Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06830031Phase 1RecruitingPrimary
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
NCT06186986Phase 3UnknownPrimary
CD30 Imaging in Diffuse Large B-cell Lymphoma
NCT03064867Phase 1Active Not RecruitingPrimary
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT03042247UnknownPrimary
Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma
NCT02531841Phase 3UnknownPrimary
High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma
Showing all 5 trials